



GREAT ORAL HEALTH

Naturally Advanced Oral Care

By Dr. Paul J. O'Malley DDS, FIADFE assisted by Thomas Soracco



Oral Probiotics—Fighting Fire with Fire!

One of the hottest topics in medicine, healing and with researchers is the vast, complex and microbial world that makes up our microbiome. These microbiota are critical to our health, our emotional well being and our very survival.

Probiotics have been best defined as “live microorganisms which when administered in adequate amounts confer a health benefit on the host.”

Increasingly over the past years, we have come to understand the critical importance of an active, healthy and balanced microbiome or microbiota—the ecological community of microorganisms that share our body space.

The discovery of pathological bacteria, and the subsequent adoption of sanitation have done much to improve our lifespans and quality

of life. But the over zealous use of antibacterial agents, chemicals, antibiotics as well as poor food choices have lead to disrupted ecologies within our bodies, particularly in the gut and the oral cavity.

It is a fact, Man needs an active and balanced ecology of bacteria both internally and externally in order to live well and to be healthy.

The oral cavity is no exception to this principle and the mouth has a very active ecology of microorganisms. Problems arise when some of these, such as the S. Mutans strain, gain strength in the colony and their life cycle byproducts (such as enamel eating acid or sulfurous gases) lead to serious problems such as dental caries, periodontal disease and chronic bad breath.

With poor oral health now connected to serious physical conditions beyond the mouth—from heart disease to chronic inflammation and even possibly the onset of migraine headaches—this is not a condition to be taken lightly.

Good, consistent oral hygiene is a key to keeping the problems under control but a powerful improvement would be to attack the problems at their source—bacterial overgrowth. Simply killing off the “bad bacteria” is a poor solution, as ALL bacteria (good and bad) are attacked and killed as well leading to a dwindling spiral of bacterial balance disruption.

The Fundamental Theory of the Use of Probiotics and Oral Health

The theory underlying the efficacy of oral probiotic bacteria is that they function by competing against oral pathogens for nutrients, growth factors and site of adhesion.

Once they adhere to the oral cavity, the probiotic bacteria aggregate and inhibit the adhesion of the harmful microorganisms by producing bacteriocins or other antimicrobial compounds such as acids or peroxides.

Therefore probiotics can help to prevent the inflammation of oral cavity and the oral tissue destruction by oral pathogens. To do so, the probiotic must adhere successfully to the surfaces of oral cavity in order to avoid or reduce its rapid exclusion from the oral cavity.

Those microorganisms that have the ability to co-aggregate are thought to have a greater advantage over non co-aggregating organisms, which are easily removed from the mouth.

First the probiotics competes with the oral pathogens for adhesion site. Once they colonize the oral surface and aggregate the oral surfaces, they then compete with extant oral pathogens for nutrients, growth factors. They also produce antimicrobial compounds—including organic acids, hydrogen peroxide, carbon peroxide, diacetyl, low molecular weight antimicrobial substances, bacteriocins, and adhesion inhibitors. This creates a double-strike mechanism of both bacteriocinic action and a “crowding out” effect.

Dental Caries: Numerous scientific studies on treating dental caries support the use of probiotics to reduce dental caries risk factors (2) (3) (4) (5) (6) (7) (8) (9). It is also important that the oral probiotics used are safe and do not introduce additional caries risk factors, such as the production of sugars. Studies on the strains *L. paracasei* and *L. reuteri*, for example, demonstrated that they do not ferment sucrose and so they are considered relatively safe probiotics in a caries-prophylactic perspective (10).

- » Studies have shown *L. paracasei* to be a key probiotic strain against dental caries risk factors. *L. paracasei* exhibited antimicrobial capacity, backed by the fact that subjects without caries are colonized by *Lactobacilli*, which possesses a significantly increased capacity to suppress growth of mutans streptococci, compared to subjects with arrested or active caries whom lacked the *Lactobacilli* (11).
- » An evaluation of the long-term effects of *L. paracasei* consumption in 122 children was done over a 12 month period. The study found that significantly reduced *S. Mutans* counts and increased *Lactobacilli* levels existed in children who consumed a probiotic with *L. paracasei* strains. At the end of this study, the test children had fewer caries lesions and a significant reduction (4.5 times) of the development of new caries lesions was observed in the high caries risk group (2).
- » Importantly, *L. paracasei* shows the ability to co-aggregate to *S. mutans* that are in suspension in saliva. This works to prevent re-adhesion to plaque thus providing the means to reduce a key caries risk factor (12).
- » A short-term clinical trial showed that *L. paracasei* has the capacity to significantly reduce the count of *S. mutans* (5). In vitro, *L. paracasei* and other *Lactobacilli* have shown an inhibitory effect against *S. mutans* and other periodontal pathogens (13).
- » *Lactobacillus* species can produce different antimicrobial components such as: organic acids, hydrogen peroxide, carbon peroxide, diacetyl, low molecular weight antimicrobial substances, bacteriocins and adhesion inhibitors that can work against *Streptococcus* and other pathogens (14).
- » A study found that the presence of *L. acidophilus* can cause reduction in the adherence of *Streptococcal* strains (15)
- » *L. reuteri* can reduce the population of *S. mutans* (9). *L. reuteri* produces reuterin, which is a broad-spectrum antimicrobial substance that works against various pathogens (16).
- » In vitro, studies have been done on the capacity of coaggregation between probiotic bacteria and caries-associated strains (this relates to the capacity to inhibit mutans streptococci). *L. acidophilus*, *L. paracasei* and *L. reuteri* show such capacity (17) (18), which means that they have the ability to prevent adhesion of caries-related bacteria to tooth surfaces.
- » *S. salivarius* M-18 is another probiotic strain that has been shown to compete (crowd out) the *S. mutans*^I strains in the colonization of oral surfaces, indicating that it can provide oral health benefits (3).
- » Moreover, *L. salivarius*, after a short-term administration trial^{II}, is capable of increasing the salivary buffering capacity and decreasing the *S. Mutans* counts (4). This means that its use as a probiotic can enhance the remineralization process and prevent the development of new caries lesions.
- » The oral administration of *L. salivarius*, in tablet form resulted in a reduced plaque index and probing pocket depth in patients who were smokers as compared to a placebo group^{III}.

^I Randomized double-blind placebo controlled trial <http://www.mdpi.com/2304-6767/3/2/43/htm>

^{II} Randomized double-blind placebo controlled trial <http://link.springer.com/article/10.1007/s12602-013-9148-9>

^{III} Randomized double-blind placebo controlled trial <http://onlinelibrary.wiley.com/doi/10.1111/j.1600-051X.2008.01306.x/abstract>

Bad Breath Treatment: Malodour afflicts 65% of Americans who expend more than \$1 billion a year on over-the-counter halitosis products, many of which are ineffective because they only mask the problem.

Halitosis is primarily a bacterial disorder of mouth. Its main source is the posterior of the tongue which is the most common site for bacteria to colonize and produce malodorous substances called volatile sulphur compounds (VSCs). VSCs are the by-products of microbial degradation of proteins, blood, mucins found in saliva, and the traces of food retained in the oral cavity.

While there are other causes for halitosis the most common reason is the imbalance of the normal microflora of the oral cavity.

Streptococcus salivarius K-12 has excellent capacity to

allivate halitosis by preemptively colonizing the oral cavity as a competitive bacterium thereby reducing the number of malodour-causing bacteria. *Streptococcus salivarius* is a pioneer colonizer of oral surfaces and is a predominant nondisease-associated member of the oral microbiota of healthy humans (19).

Streptococcus salivarius K-12 is known to produce at least two bacteriocins and clinically, in vitro, *S. salivarius* strains showed inhibitory activity against various halitosis-associated bacteria (20) (21) (22).

L. salivarius also has anti-halitosis properties, in a clinical study it showed capacity to decrease oral malodour parameter after 2 weeks of administration (23).^I

^I Open label trial [http://www.oooojournal.net/article/S1079-2104\(10\)00209-X/abstract](http://www.oooojournal.net/article/S1079-2104(10)00209-X/abstract)



Periodontal Use and Gum Disease: Periodontal disease starts with plaque formation, progressing with the inflammation of dental tissues and the associated connective tissue.

Probiotics have demonstrated a lowering of the pH of the saliva and a production of antioxidants that absorb key elements required for the formation of plaque—now the associated plaque-forming bacteria is inhibited from, or unable to, form plaque. In this manner, probiotics work to help prevent periodontal diseases. The findings from numerous studies show encouraging results in the use of probiotics to treat gingivitis, periodontitis and to control plaque levels. Additionally, studies have shown that oral probiotics can cause a significant reduction in the number of periodontopathogens present in plaque .

This all ties in with the generally held consideration that three factors are responsible for the occurrence of periodontal disease: 1) the presence of a susceptible host, 2) the presence of pathogens and 3) low levels of beneficial microbiota. By competing with, or killing off, pathogens and by increasing levels of beneficial microbiota oral probiotics provide effective treatment against two of these three factors and so working to help prevent the occurrence of disease.

Lactobacillus reuteri has clinically been shown to be efficacious in reducing both gingivitis and plaque in patients with moderate to severe gingivitis. In a 2005 double blind, placebo-controlled study on 59 randomly selected patients with moderate-to-severe gingivitis, they evaluated the oral benefits of two different strains of *L. reuteri*. All of the patients first received a plaque removal pretreatment. They were then divided into three groups and twice daily one group received a placebo and the other two groups received different strains of *L. reuteri*. After two weeks, the results showed a significant reduction in plaque scores for both the probiotic receiving groups with no reduction in the plaque scores for placebo group (24). This finding was confirmed by other studies on the use of *L. reuteri* to inhibit the formation of plaque and deliver anti-inflammatory and antimicrobial effects.

Beneficial Periodontal Results from *Lactobacillus* Strains:

- » The use of *L. reuteri* can be recommended as a useful adjunct to periodontal treatment (25) especially in patients with chronic periodontitis (26)
- » A short-term administration of *L. reuteri* has been shown to reduce the bleeding on probing and levels of pro-inflammatory cytokines in gingival crevicular fluid (27)
- » After the administration of daily tablets, *L. reuteri* demonstrated the clinical capacity to significantly reduce the count of *Prevotella intermedia* and *Porphyromonas gingivalis*—which are periodontal pathogens (28)
- » In vitro, *L. acidophilus* strongly inhibits *Porphyromonas gingivalis*—that is a known periodontal pathogen (29).
- » *L. acidophilus* has inhibitory effects on the secretion of IL1B, IL6 and IL8—which are cellular inflammatory responses induced by *P. gingivalis* (30)
- » *L. salivarius*, when administered for 4 weeks, showed beneficial effects on bleeding and on probing depths from periodontal pockets (23)
- » In vitro, *L. salivarius* and *L. paracasei* showed inhibitory effects against *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans* (13)

Yeast Infections and Oral Candida: *C. albicans* is a leading cause of fungal infection in oral cavity; it is particularly common in the elderly and in immuno-compromised patients.

While many encouraging results have been seen, further studies are needed on the effectiveness of probiotics in controlling oral candida.

- » An in-vitro study showed that *S. thermophilus* inhibits adhesion by *Candida albicans* (31)
- » *S. salivarius* K-12 inhibits adhesion by *Candida albicans* to denture acrylic surfaces and to oral mucosa. This finding pointed it out as a useful probiotic for oral care (32)
- » *L. paracasei* and *L. reuteri* showed total and moderate capacity to inhibit candida growth in-vitro (17)
- » In a 2010 study, *Candida* growth was reduced by all the lactobacilli strains tested but the effect was weaker than for *S. mutans* reduction. The strongest inhibition on *Candida albicans* was displayed by *L. reuteri* and two *L. plantarum* strains (39)

Oral Probiotics and Ear/Throat Infections: Italian researchers studied 40 adults with a history of frequent strep throat infections and/or tonsillitis. They were divided into two groups and for 90 days, one group was given the oral probiotic BLIS K12, while the other group went untreated. All patients were then followed for 6 months after the 90-day treatment period. The oral probiotic group saw an 80% reduction in infections during the treatment period and a 60% reduction over the full 6 months. The placebo group saw no change in the incidence of strep throat and tonsillitis (40).

Another study investigating the use of BLIS K12 for throat infections and ear infections among children showed similar results. One group was given the oral probiotic for 90 days and the other two groups took a placebo or nothing. Those that took BLIS K12 showed a 90% reduction in throat infections and there was a 40% reduction in ear infections. In addition, during a six-month follow-up period when the children were not taking the oral probiotics, those who had taken the oral probiotics for the 90-days had a 65% overall reduction in reported ear and throat infections (41).



REFERENCES

1. Probiotics in Food. FAO/WHO. 2001, *FAO Food and Nutrition Paper*.
2. Teanpaisan, R, y otros, y otros. Effect of Long-Term Consumption of *Lactobacillus paracasei* SD1 on Reducing Mutans Streptococci and Caries Risk: A Randomized Placebo-controlled Trial. *Dent J*. 2015, 3, págs. 43-54.
3. Burton, J, y otros, y otros. Influence of the probiotic *Streptococcus salivarius* strain M18 on indices of dental health in children: a randomized double-blind, placebo controlled trial. *Journal of Medical Microbiology*. 2013, Vol. 62, págs. 875-884.
4. Nishihara, T, y otros, y otros. Effects of *Lactobacillus salivarius*-containing tablets on caries risk factors: a randomized open-label clinical trial. *BMC Oral Health*. 2014, 4, págs. 110-106.
5. Holz, C, y otros, y otros. *Lactobacillus paracasei* DSMZ16671 Reduces Mutans Streptococci: A Short-Term Pilot Study. 2013, 5, págs. 259-263.
6. Chuang, L-C, y otros, y otros. Probiotics *Lactobacillus paracasei* effect on cariogenic bacterial flora. *Clinical Oral Investigation*. 2011, Vol. 15, págs. 472-476.
7. Singh, R, Damle, S.G. y Chawla, A. Salivary mutans streptococci and lactobacilli modulations in young children on consumption of probiotic ice-cream containing *Bifidobacterium lactis* Bb12 and *Lactobacillus acidophilus* La5. *Acta Odontologica Escandinava*. 2011, Vol. 69, 6, págs. 389-394.
8. Calgar, E., y otros, y otros. Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and lactobacilli. *clinical Oral Investigations*. 2007, 11, págs. 425-429.
9. Calgar, E., y otros, y otros. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium *Lactobacillus reuteri* ATCC 55730 by straws or tablets. *Acta odontologica Escandinava*. 2006, Vol. 64, págs. 314-318.
10. Jindal, G, y otros, y otros. Can early exposure to probiotics in children prevent dental caries? a current perspective. *Journal of Oral Biology and Craniofacial Research*. 2012, Vol. 2, 2, págs. 110-115.
11. Simark-Mattsson, C., y otros, y otros. *Lactobacillus*-mediated interference of mutans streptococci in caries-free vs caries-active subjects. *Eur J Oral Sci*. 2007, Vol. 115, 4, págs. 308-314.
12. Tanzer, J.M., y otros, y otros. Caries Inhibition by and safety of *Lactobacillus paracasei* DSMZ16671. *J Dent Res*. 2010, Vol. 89, 9, págs. 921-926.
13. Teanpaisan, R., Piwat, S, y Dahlén, G. Inhibitory effect of oral *Lactobacillus* against oral pathogens. *Letters in Applied Microbiology*. Vol. 53, págs. 452-459.
14. Silvia, M, y otros, y otros. Antimicrobial Substance from human *Lactobacillus* strain. *Antimicrob Agents Chemother*. 1987, Vol. 31, págs. 1231-1233.
15. Tahmourespour, A y Kermanshahi, R.K. The Effect of a Probiotic Strain (*Lactobacillus acidophilus*) on the plaque formation of oral Streptococci. *Bosnian Journal of Basic Medical Science*. 2010, Vol. 11, 1, págs. 37-40.
16. Axelsson, L.T, y otros, y otros. Production of Broad-spectrum antimicrobial substance by *Lactobacillus reuteri*. *Microbial Ecology in Health and Disease*. 1989, Vol. 2, págs. 131-136.
17. Hasslöf, P, y otros, y otros. Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli - an in vitro study. *BMC Oral Health*. 2010, Vol. 10, 18.
18. Tweetman, L, y otros, y otros. Coaggregation between probiotic bacteria and caries-associated strains: An in vitro study. *Acta Odontologica Scandinavica*. 2009, Vol. 67, 5, págs. 284-288. ABSTRACT ONLY.
19. Kazor, C.E., y otros, y otros. Diversity of Bacterial Population on The Tongue Dorsa of Patients with Halitosis and Healthy Patients. *Journal of Clinical Microbiology*. 2003, Vol. 41, 2, págs. 558-563.
20. Tagg, J.R. y Dierksen, K.P. Bacterial replacement therapy: adapting 'germ warfare' to infection prevention. *Trends Biotechnol*. 2003, 21, págs. 217-223.
21. Burton, J.P., y otros, y otros. A preliminary study of the effect of probiotic *Streptococcus salivarius* K-12 on oral malodour parameters. *Journal of Applied Microbiology*. 2006, Vol. 100, págs. 754-764.
22. Masdea, L., y otros, y otros. Antimicrobial activity of *Streptococcus salivarius* K-12 on bacteria involved in oral malodour. *Archives of Oral Biology*. 2012.
23. Iwamoto, T, y otros, y otros. Effects of probiotic *Lactobacillus salivarius* WB21 on halitosis and oral health: an open-label pilot trial. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2010, Vol. 110, págs. 201-208.
24. Krasse, P, y otros, y otros. Decreased gum bleeding and reduced gingivitis by the probiotic *Lactobacillus reuteri*. *Swedish Dental Journal*. 2006, Vol. 30, 2, págs. 55-60. ABSTRACT ONLY.
25. Vivekananda, M.R., Vandana, K.L. y Bhat, K.G. Effect of the probiotic *Lactobacilli reuteri* (Prodentis) in the management of periodontal disease: a preliminary randomizes clinical trial. *Journal of Oral Microbiology*. 2010, Vol. 2.
26. Teughels, W, y otros, y otros. Clinical and microbiological effects of *Lactobacillus reuteri* probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. *J Clin Periodontol*. 2013, 40, págs. 1025-1035.
27. Tweetman, S, y otros, y otros. Short-term effect of chewing gums containing probiotic *Lactobacillus reuteri* on the levels of inflammatory mediator in gingival crevicular fluid. *Acta Odontologica Scandinavica*. 2009, 67, págs. 19-24.
28. Iniesta, M, y otros, y otros. Probiotic effects of orally administrated *Lactobacillus reuteri*-containing tables on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. *Journal of Clinical Periodontology*. 2012, Vol. 39.
29. Zhao, JJ, Le, KY y Ma, L. Antagonistic effects of *Lactobacillus acidophilus* and *Bifidobacterium* adolescents on periodontal pathogens in vitro. *Shanghai Journal of Stomatology*. 2011, Vol. 20, 4, págs. 364-367. ABSTRACT ONLY.
30. Zhao, JJ, Feng, X y Le, K. Effect of *Porphyromonas gingivalis* and *Lactobacillus acidophilus* on secretion of IL1B, IL6 and IL8 by gingival Epithelial Cells. *Inflammation*. 2012, Vol. 35, 4, págs. 1330-1337. ABSTRACT ONLY.
31. Busscher, HJ, y otros, y otros. *Streptococcus thermophilus* and its Bio-surfactants Inhibit Adhesion by *Candida* spp. on Silicone Rubber. *Applied and Environmental Microbiology*. 1997, Vol. 63, págs. 3810-3817.
32. Ishijima, S, y otros, y otros. Effects of *Streptococcus salivarius* K12 on the In Vitro Growth of *Candida albicans* and Its Protective Effect in an Oral Candidiasis Model. *Applied and Environmental Microbiology*. págs. 2190-2199.
33. Flichy-Fernández, AJ, Ata-Ali, J y Alegre, T. The effect of orally administrated probiotic *Lactobacillus reuteri*-containing Tablets in peri-implant mucositis: a double-blind randomized controlled trial. *Journal of Periodontal Research*. 2015. ABSTRACT ONLY.
34. Timmerman, HM, y otros, y otros. Monostrain, multistain and multispecies probiotics - A comparison of functionality and efficacy. *Intrnational Journal of Food Microbiology*. 2004, Vol. 96, 13, págs. 219-233. ABSTRACT ONLY.
35. Chapman, CMC, Gibson, GR y Rowland, I. In Vitro evaluation of single- and multi-strain probiotics: Interspecies inhibition between probiotics strains, and inhibition of pathogens. *Anaerobe*. 2012, Vol. 18, 4, págs. 405-413. ABSTRACT ONLY.
36. Cogulu, D, y otros, y otros. Potential effects of a multistrain probiotic-kefir on salivary *Streptococcus mutans* and *Lactobacillus* spp. *Journal of Dental Sciences*. 2010, Vol. 5, 3, págs. 144-149. ABSTRACT ONLY.
37. Chapman, CMC, Gibson, GR y Rowland, I. Health benefits of probiotics: are mixtures more effective than single strain? *European Journal of Nutrition*. 2011, Vol. 50, 1, págs. 1-17. ABSTRACT ONLY.
38. Shimauchi et al. Improvement of periodontal condition by probiotics with *Lactobacillus salivarius* WB21: a randomized, double-blind, placebo-controlled study *Journal of Clinical Periodontology*, August 2008
39. Pamela Hasslöf, Maria Hedberg, Svante Tweetman, Christina Stecksén-Blicks. Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli—an in vitro study. *BMC Oral Health* July 2010
40. Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C. Clinical evaluation of the oral probiotic *Streptococcus salivarius* K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by *Streptococcus pyogenes* in adults. *Expert Opin Biol Ther*. 2013 Mar;13(3):339-43.
41. Di Pierro F, Donato G, Fomia F, Adami T, Careddu D, Cassandro C, Albera R. Preliminary pediatric clinical evaluation of the oral probiotic *Streptococcus salivarius* K12 in preventing recurrent pharyngitis and/or tonsillitis caused by *Streptococcus pyogenes* and recurrent acute otitis media. *Int J Gen Med*

Advanced Oral Probiotics from Great Oral Health

There are other oral probiotic products in the market but they don't have our unique blend of 7 strains. Each strain was chosen according to its specific benefits and for the synergistic action when they act together, meeting the high requirements that we at Great Oral Health demand for the products we manufacture and sell.

Streptococcus salivarius (BLIS K-12), Streptococcus salivarius (BLIS M-18), Streptococcus thermophilus, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus paracasei, Lactobacillus reuteri

Available on Amazon or on our website: Just search for Great Oral Health or go directly to www.amazon.com/gp/shops/greatoralhealth

CONTACT US: info@greatoralhealth.com

VISIT US: www.greatoralhealth.com